Decoding the influence of mitochondrial Ca2+ regulation on neurodegenerative disease progression

January 27, 2025 02:07 PM GMT | By EIN Presswire
 Decoding the influence of mitochondrial Ca2+ regulation on neurodegenerative disease progression
Image source: EIN Presswire

GA, UNITED STATES, January 27, 2025 /EINPresswire.com/ -- Mitochondria are critical for cellular homeostasis, regulating bioenergetics, redox balance, Ca2+ signaling, and cell death. Mitochondrial Ca2+ (Ca2+mito) plays a dual role in physiological processes like ATP production and pathophysiological events, including cell death and cancer. The balance of Ca2+ uptake and efflux, mediated by mitochondrial transporters and mitochondria-endoplasmic reticulum contact sites (MERCS), is essential for maintaining Ca2+mito homeostasis. This review summarizes current insights into mitochondrial Ca2+ regulation, its roles in physiology and neurodegenerative diseases, and explores therapeutic strategies targeting Ca2+ homeostasis, including innovative drug delivery systems and calcium-modulating agents.

Mitochondria are crucial organelles for cellular homeostasis, regulating processes such as ATP production, reactive oxygen species (ROS) management and Ca2+ signaling. In particular, mitochondrial Ca2+ plays a dual role: enabling physiological functions like metabolism and ATP synthesis while contributing to pathological processes such as apoptosis and oxidative stress when dysregulated. The balance of mitochondrial Ca2+ is maintained through interactions between uptake and efflux mechanisms. Key players in the process include the mitochondrial calcium uniporter (MCU) complex for Ca2+ influx and the Na+/Ca2+ exchanger (NCLX) for efflux. The mitochondria-endoplasmic reticulum contact sites (MERCS) also play a pivotal role in facilitating Ca2+ transfer. Dysregulation at any level, such as excessive uptake or impaired efflux, leads to mitochondrial Ca2+ overload, triggering ROS production, mitochondrial membrane potential loss, and permeability transition pore activation, which can culminate in cell death.

A review by a team of researchers at the Chinese Academy of Science highlights the role of mitochondrial Ca2+ imbalance in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and spinocerebellar ataxias (SCAs).

In AD, amyloid-beta (Aβ) disrupts mitochondrial Ca2+ homeostasis by enhancing Ca2+ uptake via MCU and impairing efflux through NCLX. These changes lead to ROS accumulation, energy depletion, and neuronal death. MERCS alterations exacerbate the pathology by increasing ER-mitochondria Ca2+ transfer.

In PD, α-synuclein aggregates disrupt MERCS, impairing Ca2+ transfer from the ER to mitochondria, while DJ-1 mutations reduce the antioxidant capacity, exacerbating oxidative stress. Mutations in several ALS-associated genes, including TAR DNA-binding protein 43 (TDP-43), superoxide dismutase 1 (SOD1), and C9orf72, have been reported to physically interact with the mitochondria and play pivotal roles in maintaining mitochondrial function.

Meanwhile, HD is caused by the expansion of CAG repeats in the huntingtin (HTT) gene, producing mutant huntingtin (mHTT) protein. In HD, mHTT increases the sensitivity of IP3R and NMDA receptors, causing abnormal cytosolic/mitochondrial Ca2+ signaling and mitochondrial dysfunction.

As for SCAs, they are a group of inherited neurodegenerative disorders caused by polyglutamine expansions in genes such as ATXN2 and ATXN3. Mutant proteins enhance IP3R-mediated Ca2+ release from the ER, resulting in excessive mitochondrial Ca2+ uptake and impaired efflux.

The review, published in the KeAi journal Mitochondrial Communications, also discusses the potential interventions targeting mitochondrial Ca2+ regulators. Strategies include modulating MCU and NCLX activity, stabilizing MERCS, and developing compounds that prevent mitochondrial Ca2+ overload. For instance, inhibitors of MCU and stabilizers of mitochondrial permeability transition pore (mPTP) show promise in preclinical models.

“In this review, we emphasize the role of Ca2+mito in both physiological and pathophysiological contexts,” says the corresponding author Tie-Shan Tang. “Developing drugs that specifically target parts of the MCU complex, NCLX, or MERCS is tricky. Hence, we need sufficient information to ensure they only affect mitochondrial Ca2+ levels where needed, without messing up the healthy tissues”.

DOI
10.1016/j.mitoco.2025.01.001

Original Source URL
https://doi.org/10.1016/j.mitoco.2025.01.001

Funding information
National Natural Science Foundation of China (Grant Nos. 8203003, 92254301, 81921006, 32070780), the National Key R&D Program of China (2023YFA1801900), the Key Laboratory of Organ Regeneration and Reconstruction, and the State Key Laboratory of Membrane Biology.

Lucy Wang
BioDesign Research
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next